About Aldagen
Aldagen is a company based in Durham (United States) founded in 2001 was acquired by Nuo Therapeutics in February 2012.. Aldagen has raised $61.53 million across 9 funding rounds from investors including Square 1 Bank, Harbert Management and Nuo Therapeutics. The company has 18 employees as of December 31, 2014. Aldagen operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter Durham, United States
- Employees 18 as on 31 Dec, 2014
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aldagen, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$61.53 M (USD)
in 9 rounds
-
Latest Funding Round
$585 K (USD), Series C
Jan 13, 2012
-
Investors
Square 1 Bank
& 10 more
-
Employee Count
18
as on Dec 31, 2014
-
Acquired by
Nuo Therapeutics
(Feb 08, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aldagen
Aldagen has successfully raised a total of $61.53M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $585 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series C — $585,004
-
First Round
First Round
(01 Feb 2002)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2012 | Amount | Series C - Aldagen | Valuation |
investors |
|
| Jun, 2011 | Amount | Series C - Aldagen | Valuation |
investors |
|
| Nov, 2009 | Amount | Series C - Aldagen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aldagen
Aldagen has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Square 1 Bank, Harbert Management and Nuo Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life sciences and tech focused VC firm funding companies in the US
|
Founded Year | Domain | Location | |
|
Infrastructure, hedge, private equity, and debt fund focused on multiple sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aldagen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aldagen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aldagen Comparisons
Competitors of Aldagen
Aldagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Aldagen
When was Aldagen founded?
Aldagen was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Where is Aldagen located?
Aldagen is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Who is the current CEO of Aldagen?
Tom Amick is the current CEO of Aldagen.
Is Aldagen a funded company?
Aldagen is a funded company, having raised a total of $61.53M across 9 funding rounds to date. The company's 1st funding round was a Series C of $7.29M, raised on Feb 01, 2002.
How many employees does Aldagen have?
As of Dec 31, 2014, the latest employee count at Aldagen is 18.
What does Aldagen do?
Aldagen was founded in 2001 in Durham, United States, focusing on regenerative medicine. Proprietary technology was utilized to isolate mesenchymal stem cells from patient bone marrow for treating vascular conditions. Clinical trials were conducted for candidates addressing critical limb ischemia, ischemic heart failure, and ischemic stroke. The company was acquired by Cytomedix, now Nuo Therapeutics, in February 2012.
Who are the top competitors of Aldagen?
Aldagen's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Who are Aldagen's investors?
Aldagen has 11 investors. Key investors include Square 1 Bank, Harbert Management, Nuo Therapeutics, Piedmont Angel Network, and Intersouth Partners.